Ropinirole
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
- Ropinirole
- Ropinirole: From Restless Legs Syndrome and Parkinson Disease to Attention Deficit-Hyperactivity Disorder
Ropinirole: From Restless Legs Syndrome and Parkinson Disease to Attention Deficit-Hyperactivity Disorder
One-Sentence Summary
Ropinirole is a dopamine D2/D3 agonist originally used to treat restless legs syndrome (RLS) and Parkinson disease. The TxGNN model predicts it may be effective for attention deficit-hyperactivity disorder (ADHD), with no registered clinical trials but 8 publications currently supporting this direction, including one recent randomized, placebo-controlled trial of ropinirole added to methylphenidate.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Restless legs syndrome, Parkinson disease (the New Zealand licence records contain no approved indication text) |
| Predicted New Indication | Attention deficit-hyperactivity disorder |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L3 |
| New Zealand Market Status | Cancelled only (no currently valid licences) |
| Number of Authorizations | 4 (all cancelled) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, ropinirole is a dopamine agonist acting on D2 and D3 receptors. Its efficacy in RLS and Parkinson disease is established, and mechanistically it may be applicable to ADHD.
ADHD involves dopaminergic dysregulation, and it frequently co-occurs with RLS, an established ropinirole indication. A shared dopaminergic and iron-metabolism pathway plausibly links the two conditions. This link is largely inferred from the RLS comorbidity. Direct efficacy of ropinirole in ADHD has not been firmly established.
Notably, a 2026 randomized trial tested ropinirole as an add-on to methylphenidate in children with ADHD. Its design is promising, but the result should be verified in the full text and replicated before drawing conclusions.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 42640474 | 2026 | RCT | Eur Child Adolesc Psychiatry | Eight-week, double-blind trial in 66 children and adolescents (6-17 years) with ADHD comparing ropinirole plus methylphenidate against placebo plus methylphenidate. The abstract is truncated, so the results could not be confirmed. |
| 15866437 | 2005 | Case report | Pediatr Neurol | A 6-year-old boy with ADHD and probable RLS/periodic limb movements, with limited response to methylphenidate, improved in both ADHD symptoms and sleep on ropinirole. |
| 16218085 | 2005 | Review | Sleep | Reviews the association between RLS and ADHD, possible underlying mechanisms, and the potential value of shared treatments. |
| 18656214 | 2008 | Review | Rev Neurol | General review of RLS (prevalence 2-3% in Western countries, diagnostic features); background for the RLS-ADHD link. |
| 34182128 | 2021 | Preclinical | Pharmacol Res | Dopamine D4 receptor variants, associated with ADHD, form heteromers with α2A adrenoceptors, which is relevant to ADHD pharmacology. |
| 17483695 | 2007 | Animal model | J Neuropathol Exp Neurol | Mouse model combining A11 lesioning and iron deprivation, supporting the dopamine-iron link in RLS. |
| 30950895 | 2019 | Case series | Cornea | Corneal edema in 3 patients exposed to systemic dopaminergic agents (an adverse-effect signal). |
| 24992083 | 2014 | Clinical study | Clin Neuropharmacol | Piribedil compared with pramipexole and ropinirole in Parkinson disease with daytime sleepiness. It concerns a different drug and disease, so its relevance to ADHD is limited. |
New Zealand Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 2310880 | Ropin | Tab 5 mg | Not recorded (cancelled) |
| 2310872 | Ropin | Tab 2 mg | Not recorded (cancelled) |
| 2310864 | Ropin | Tab 1 mg | Not recorded (cancelled) |
| 2310856 | Ropin | Tab 0.25 mg | Not recorded (cancelled) |
Safety Considerations
- Contraindications flagged in the knowledge graph (not label text): multiple system atrophy, postural orthostatic tachycardia syndrome, orthostatic hypotension, drug-induced dyskinesia, liver failure, psychotic disorder, schizophreniform disorder, mental disorder, schizoaffective disorder, hypotensive disorder.
- Pharmacological targets: dopamine D2 receptor (DRD2) and D3 receptor (DRD3). No specific drug-drug interaction entries were identified.
- Literature signals: corneal edema with systemic dopaminergic agents, and an increased risk of gambling disorder in a Swedish nationwide register study of ropinirole, pramipexole and aripiprazole.
Please also refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN score is very high and a recent randomized trial exists, but there are no registered trials, the trial result is unconfirmed, and the other evidence is mostly case reports, reviews and preclinical work (L3). In addition, there are no currently valid New Zealand licences and the safety data are incomplete, so the drug is not ready to advance.
To proceed, the following is needed:
- Full-text review of the 2026 RCT (PMID 42640474) to confirm efficacy, safety and effect size
- Independent replication in larger, multi-centre trials, ideally registered
- Detailed mechanism of action data
- Package insert warnings and contraindications from Medsafe
- Review of the regulatory pathway, since all four New Zealand licences are cancelled
- A safety plan covering impulse-control and gambling risk, psychiatric effects, orthostatic hypotension and paediatric use
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.